ep short consensu petx ep
miss estim stronger revenu off-set
weaker profit driven million impair charg relat
lower ep
mileston time pt remain
revenu ahead strength big three total revenu
million slightli plan million driven gallipr licens
collabor revenu million relat product sale
million buoy million tailwind relat transfer
gallipr inventori elanco nocita sale increas million vs
ahead view estimate million entyc sale
million million estim reflect first two month
commerci sale cog million plan
expens declin million yoy million due lower mileston
payment fewer on-going pivot studi note margin
improv go forward gallipr revenu expect deriv
strictli royalti begin sg expens declin slightli
yoy contribut consolid net loss million reserv
stand million estim suffici fund oper
debt oblig least
pre-cal view earn report typic meaning catalyst pet
biotech compani focu confer call tomorrow like
growth galliprant/nocita earli entyc adopt
aforement impair charg pipelin updat nocita felin
full licensur studi progress futur collabor
natur new relationship askat addit eager
hear manag financi expect gallipr move forward
petx longer recogn associ product relat revenu
begin risk includ unanticip commerci delay weaker
expect adopt recent launch product
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
petx companion anim therapeut compani focus
licens develop commerci biopharmaceut
product companion anim
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum higher peak sale key
product includ gallipr nocita entyc acceler
timelin addit product launch greater probabl
success meaning competit core product
grey sky scenario assum lower peak sale
key product current model meaning
contribut addit product develop well
potenti liquid profit issu
 close
earn report close book busi quarter petx detail recap
quarter recent petx newsflow shown
march petx establish research develop collabor
japanes life scienc compani askat inc agreement includ option
pain allergi cancer categori
interestingli askat employe previous play key role discoveri
compound licens develop petx two fda approv
januari petx gallipr canin osteoarthr therapeut grant
market author europ gallipr midst ramp us
entri new market addit notabl conjunct
earn releas report million sale gallipr estim
drug captur oral nsaid market consist feedback
recent veterinari survey indic mani veterinarian view
gallipr safer altern zoetiss rimadyl nsaid option
accord survey respond current prescrib gallipr
particip also list gallipr second impact recent product launch
industri trail zoetiss cytopoint
figur oral nsaid market size gallipr market share
clinic studi
decemb petx grant condit usda licens canin
osteosarcoma vaccin therapeut treatment dog age one year inflict
osteosarcoma data
own dog
osteosarcoma show increas median surviv time day vs day
histor control group test subject treat primari tumor
remov four dose carboplatin chemotherapi follow
therapeut vaccin everi three week three dose accord
usda regul obtain full licensur therapeut petx commenc
extend field studi earli make avail approxim two dozen
decemb petx receiv target anim safeti technic section complet
letter nocita felin fda note cat contain
activ compound legaci nocita post-op analgesia product dog
commerci launch oct importantli petx submit major
technic section fda plan expand exist nocita label includ
cat upon full approv conjunct earn releas petx note
anticip file nada assum fda approv effect
decemb petx enter sale agreement cowen
petx issu million common stock cowen subject
commiss potenti dilut limit petx potenti upsid extent
may prove import sourc liquid near term conjunct today
earn releas petx reveal receiv million januari sale
term neg news decemb petx partner vetstem biopharma
releas pivot field effect safeti studi result adipose-
deriv allogen stem cell therapeut candid osteoarthr pain canin
result achiev protocol-defin efficaci success criteria petx/vetstem
plan revisit collabor review studi result
discuss potenti tomorrow call
oper metric valuat
petx report cash reserv million decemb provid
suffici liquid fund oper least view
manag expect spend million fund day-to-day oper million
debt servic
importantli sg expens stabil corpor infrastructur substanti
place support commerci effort relat gallipr nocita entyc howev
sg expect rise slightli petx seek increas awar adopt
three commerci avail therapeut aforement million receiv
januari share issuanc provid ad flexibl tp base
stronger profil gallipr nocita entyc
compani mention price
